1306 related articles for article (PubMed ID: 36858871)
21. Strong Decay of SARS-CoV-2 Spike Antibodies after 2 BNT162b2 Vaccine Doses and High Antibody Response to a Third Dose in Nursing Home Residents.
Blain H; Tuaillon E; Gamon L; Pisoni A; Miot S; Picot MC
J Am Med Dir Assoc; 2022 May; 23(5):750-753. PubMed ID: 35311651
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity of Monovalent mRNA-1273 and BNT162b2 Vaccines in Children <5 Years of Age.
Dalapati T; Williams CA; Giorgi EE; Hurst JH; Herbek S; Chen JL; Kosman C; Rotta AT; Turner NA; Pulido N; Aquino JN; Pfeiffer TS; Rodriguez J; Fouda GG; Permar SR; Kelly MS
Pediatrics; 2024 Jun; 153(6):. PubMed ID: 38548700
[TBL] [Abstract][Full Text] [Related]
23. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
[TBL] [Abstract][Full Text] [Related]
24. Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients.
Kawashiro K; Suzuki R; Nogimori T; Tsujino S; Iwahara N; Hirose T; Okada K; Yamamoto T; Fukuhara T; Hotta K; Shinohara N
Sci Rep; 2024 May; 14(1):12176. PubMed ID: 38806644
[TBL] [Abstract][Full Text] [Related]
25. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
[TBL] [Abstract][Full Text] [Related]
26. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
[TBL] [Abstract][Full Text] [Related]
27. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.
Lasagna A; Bergami F; Lilleri D; Percivalle E; Quaccini M; Alessio N; Comolli G; Sarasini A; Sammartino JC; Ferrari A; Arena F; Secondino S; Cicognini D; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
ESMO Open; 2022 Apr; 7(2):100458. PubMed ID: 35427842
[TBL] [Abstract][Full Text] [Related]
29. Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.
Wang XJ; Yao L; Zhang HY; Zhu KL; Zhao J; Zhan BD; Li YK; He XJ; Huang C; Wang ZY; Jiang MD; Yang P; Yang Y; Wang GL; Wang SQ; Dai EH; Gao HX; Ma MJ
Genome Med; 2022 Dec; 14(1):146. PubMed ID: 36581867
[TBL] [Abstract][Full Text] [Related]
30. Cross neutralization of SARS-CoV-2 omicron subvariants after repeated doses of COVID-19 mRNA vaccines.
Luczkowiak J; Rivas G; Labiod N; Lasala F; Rolo M; Lora-Tamayo J; Mancheno-Losa M; Rial-Crestelo D; Pérez-Rivilla A; Folgueira MD; Delgado R
J Med Virol; 2023 Jan; 95(1):e28268. PubMed ID: 36319593
[TBL] [Abstract][Full Text] [Related]
31. Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5.
Kawasuji H; Morinaga Y; Tani H; Saga Y; Yamada H; Yoshida Y; Takegoshi Y; Kaneda M; Murai Y; Kimoto K; Ueno A; Miyajima Y; Nagaoka K; Ono C; Matsuura Y; Niimi H; Yamamoto Y
Microbiol Spectr; 2023 Mar; 11(2):e0513122. PubMed ID: 36946738
[TBL] [Abstract][Full Text] [Related]
32. Immunity against Delta and Omicron variants elicited by homologous inactivated vaccine booster in kidney transplant recipients.
Zhang L; Yang J; Lai C; Wan L; Xiong S; Kong W; Liu Z; Yu P; Chen M; Mai W; Khan SA; Deng M; Chen L; Lei Y; Zhou Q; Yu N; Li P; Chen Z; Ji T
Front Immunol; 2022; 13():1042784. PubMed ID: 36700230
[TBL] [Abstract][Full Text] [Related]
33. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection.
Gilboa M; Regev-Yochay G; Mandelboim M; Indenbaum V; Asraf K; Fluss R; Amit S; Mendelson E; Doolman R; Afek A; Freedman LS; Kreiss Y; Lustig Y
JAMA Netw Open; 2022 Sep; 5(9):e2231778. PubMed ID: 36107426
[TBL] [Abstract][Full Text] [Related]
34. Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection: Implications for boosting.
Batra G; Murugesan DR; Raghavan S; Chattopadhyay S; Mehdi F; Ayushi ; Gosain M; Singh S; Das SJ; Deshpande S; Sonar S; Jakhar K; Bhattacharya J; Mani S; Pandey AK; Sankalp ; Goswami S; Das A; Dwivedi T; Sharma N; Kumar S; Sharma P; Kapoor S; Kshetrapa P; Wadhwa N; Thiruvengadam R; Kumar R; Gupta R; Garg PK; Bhatnagar S
Indian J Med Res; 2023 Jun; 157(6):509-518. PubMed ID: 37322634
[TBL] [Abstract][Full Text] [Related]
35. Pronounced antibody elevation after SARS-CoV-2 BNT162b2 mRNA booster vaccination in nursing home residents.
Chong Y; Goto T; Tani N; Yonekawa A; Ikematsu H; Shimono N; Tanaka Y; Akashi K
Influenza Other Respir Viruses; 2022 Nov; 16(6):1066-1071. PubMed ID: 35962568
[TBL] [Abstract][Full Text] [Related]
36. Early humoral and cellular responses after bivalent SARS-CoV-2 mRNA-1273.214 vaccination in long-term care and retirement home residents in Ontario, Canada: An observational cohort study.
Breznik JA; Rahim A; Bhakta H; Clare R; Zhang A; Ang J; Stacey HD; Liu LM; Kennedy A; Bilaver L; Hagerman M; Kajaks T; Bramson JL; Nazy I; Miller MS; Costa AP; Bowdish DME;
J Med Virol; 2023 Oct; 95(10):e29170. PubMed ID: 37822054
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of a Second COVID-19 Vaccine Booster Dose Against Infection, Hospitalization, or Death Among Nursing Home Residents - 19 States, March 29-July 25, 2022.
McConeghy KW; White EM; Blackman C; Santostefano CM; Lee Y; Rudolph JL; Canaday D; Zullo AR; Jernigan JA; Pilishvili T; Mor V; Gravenstein S
MMWR Morb Mortal Wkly Rep; 2022 Sep; 71(39):1235-1238. PubMed ID: 36173757
[TBL] [Abstract][Full Text] [Related]
39. Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination.
Assawakosri S; Kanokudom S; Suntronwong N; Auphimai C; Nilyanimit P; Vichaiwattana P; Thongmee T; Duangchinda T; Chantima W; Pakchotanon P; Srimuan D; Thatsanatorn T; Klinfueng S; Yorsaeng R; Sudhinaraset N; Wanlapakorn N; Mongkolsapaya J; Honsawek S; Poovorawan Y
J Infect Dis; 2022 Oct; 226(8):1372-1381. PubMed ID: 35267040
[TBL] [Abstract][Full Text] [Related]
40. A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds.
Usdan L; Patel S; Rodriguez H; Xu X; Lee DY; Finn D; Wyper H; Lowry FS; Mensa FJ; Lu C; Cooper D; Koury K; Anderson AS; Türeci Ö; Şahin U; Swanson KA; Gruber WC; Kitchin N;
Clin Infect Dis; 2024 May; 78(5):1194-1203. PubMed ID: 38016021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]